Iterum Therapeutics Plc (ITRM) Stock Price, Quote & News

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 903 8354

Website: www.iterumtx.com

Address:

3 Dublin Landings, North Wall Quay, Dublin, Ireland

NapoleonDynamiteCapital Feb. 4 at 12:57 AM

$ITRM So the drug is a winner, but y'all are gonna lose everything? How is that even possible? You have the shittiest CEO in history. Maybe Alex Denner can come save you? You need an activist investor to take over the Board and boot those bums out. Still watching, not sure I want a piece of this sweet action...

2 · Reply

yellowjacker Feb. 4 at 12:54 AM

$ITRM I just talked to Gemini and nailed down the perfect solution. A major licensing agreement with European and Asian pharma would give us a up front payment to pay Pfizer off, meet the Nasdaq cash level of 35 million needed, and be granted a 180 day extention or push the stock above a 1.00 for 10 days, allowing us to grow our script count. This all coming on a yes FDA step-down letter and an approved 3 contract on A PBM. This would eliminate the proxy vote, and happy days are here again.

1 · Reply

Twills08 Feb. 3 at 11:39 PM

$ITRM Agreed

0 · Reply

Jorl Feb. 3 at 11:30 PM

$ITRM i believe their attempt to sway the vote was through those last few weekly PRs in nov/dec. i don’t anticipate to hear anything until feb 18 unfortunately. i’d like to be proven wrong via FDA response, but making assumptions and giving them the benefit of the doubt has lost me a lot of money here also, the RSS and dilution are separate proposals. while the RSS will be painful, it might not be as painful without added dilution. this could encourage them to still meet the MVLS organically by the june requirement. for the record, i am voting no across the board. i think a no vote pushes them to pursue a BO quickly. post-bankruptcy acquisitions and asset auctions are tricky. in most cases they would prefer to act before then

2 · Reply

Bobcar888 Feb. 3 at 10:50 PM

$ITRM Anybody from 5 years ago remember when the analysts said their balance sheet was stronger than Fort Knox? Guess it was an inside job. 🤣 Extremely frustrated we're here again facing a reverse split and dilution. Remember thinking/ no way people will vote in favor of split and dilution. It happen -- my guess is this reverse split will be higher to get rid of retail -and dilution and rs will be immediate. The conceptualized and touted targeted commercialization plan in the deck -- seems to be a failure-- hoping to be wrong. Do you even think they have a Plan B, hail mary plan or are they still mailing it in? this is rhetorical.

2 · Reply

StonkZombie Feb. 3 at 10:49 PM

$ITRM Personally I think this whole "stepdown letter from the FDA" theory is getting ridiculous. Because that all it appears to be, a theory. Not a shred of evidence points to this being a real thing. Just show me *something* where the FDA said they were going to reply with "a letter" and I'll let it go. Because it's starting to sound like Coyne's mysterious 8K that never dropped but was supposed to drop ("by law"), and by all accounts should have, but then never did... and then that was it. Just a fairy tale that meant nothing. No 8K. No explanation. It just got forgotten. Which in another couple of weeks will be The End to this so called FDA letter. If you wonder why there are people here that can't take this company seriously and call it a scam, these are reasons why. Unless someone can show me something concrete to the contrary. And.... go

2 · Reply

Schindelegger Feb. 3 at 10:46 PM

$ITRM Iterum is not behaving in any way that they are in a silence period, they have never been vocal, so not sure where this is coming from. Apparently we are awaiting a step down letter from the FDA, there is not even evidence that an official application has been filed. People are promoting to vote ‘Yes’, now this is reaching comlete retardiness. Please do your on DD before you make such an educated decision. Vote ‘No’ and for once allow the company to search for alternative and non dilutive financing!

3 · Reply

Biorocksme Feb. 3 at 10:40 PM

$ITRM The only step down with real world data is this stock price.

0 · Reply

Shawshank256 Feb. 3 at 10:22 PM

$ITRM yesterday 1.1 mil avail to borrow ,today 1.8mil ,both days 76-77% dark pool trading vol with accumulation up

0 · Reply

ibraa1313 Feb. 3 at 9:53 PM

$ITRM $ITRM Hello everyone. I'd like to vote, but of course the answer is NO to everything! I live in Switzerland. I haven't received any emails or calls. If you could guide me, I'd appreciate it. Thank you.

1 · Reply

Iterum Therapeutics Provides Business Update

Nov 14, 2025, 11:11 AM EST - 2 months ago

Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript

Nov 14, 2025, 7:00 AM EST - 2 months ago

Iterum Therapeutics Reports Third Quarter 2025 Financial Results

Nov 7, 2025, 8:00 AM EST - 3 months ago

Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025

Oct 14, 2025, 8:30 AM EDT - 4 months ago

Iterum Therapeutics to Present Data at IDWeek 2025

Aug 20, 2025, 8:00 AM EDT - 5 months ago

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.

Aug 5, 2025, 4:58 PM EDT - 6 months ago

Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:00 AM EDT - 6 months ago

Iterum Therapeutics Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 8:00 AM EDT - 6 months ago

Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 2, 2025, 4:30 PM EDT - 7 months ago

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 7:00 AM EDT - 7 months ago

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

Jun 25, 2025, 7:00 AM EDT - 7 months ago

Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

Jun 11, 2025, 7:00 AM EDT - 8 months ago

Iterum Therapeutics Announces Partnership for Commercialization Services

May 19, 2025, 7:00 AM EDT - 9 months ago

Iterum Therapeutics Announces Extension of Term of Promissory Note

May 13, 2025, 1:44 PM EDT - 9 months ago

Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:00 AM EDT - 9 months ago

Iterum Therapeutics Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 9 months ago

Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 30, 2025, 4:30 PM EDT - 9 months ago

Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Apr 29, 2025, 8:00 AM EDT - 10 months ago

Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares

Apr 14, 2025, 8:00 AM EDT - 10 months ago

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

Feb 7, 2025, 10:20 AM EST - 1 year ago

Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript

Feb 7, 2025, 7:00 AM EST - 1 year ago

Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 31, 2025, 8:00 AM EST - 1 year ago

Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025

Nov 21, 2024, 8:30 AM EST - 1 year ago

Iterum Therapeutics Regains Full Nasdaq Compliance

Nov 14, 2024, 1:14 PM EST - 1 year ago

Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:00 AM EST - 1 year ago

Iterum Therapeutics Reports Third Quarter 2024 Financial Results

Oct 28, 2024, 10:27 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript)

Oct 28, 2024, 5:00 AM EDT - 1 year ago

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Oct 25, 2024, 11:03 AM EDT - 1 year ago

Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Oct 25, 2024, 10:57 AM EDT - 1 year ago

US FDA approves Iterum's treatment for urinary infection

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Iterum Therapeutics to Present Data at IDWeek 2024

Oct 9, 2024, 5:00 PM EDT - 1 year ago

Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit

Sep 6, 2024, 4:30 PM EDT - 1 year ago

Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference

Aug 16, 2024, 11:27 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:00 AM EDT - 1 year ago

Iterum Therapeutics Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Aug 6, 2024, 5:30 PM EDT - 1 year ago

Iterum Therapeutics Announces Expiration and Results of Rights Offering

Aug 2, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem

Jul 22, 2024, 7:30 AM EDT - 1 year ago

Iterum Therapeutics Commences Rights Offering

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

May 31, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

May 13, 2024, 9:49 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q1 2024 Earnings Call Transcript

May 13, 2024, 7:00 AM EDT - 1 year ago

Iterum Therapeutics Reports First Quarter 2024 Financial Results

May 6, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Mar 28, 2024, 10:08 AM EDT - 2 years ago

Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 21, 2024, 4:30 PM EDT - 2 years ago

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat

Jan 30, 2024, 7:00 AM EST - 2 years ago

Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

NapoleonDynamiteCapital Feb. 4 at 12:57 AM

2 · Reply

yellowjacker Feb. 4 at 12:54 AM

1 · Reply

Twills08 Feb. 3 at 11:39 PM

$ITRM Agreed

0 · Reply

Jorl Feb. 3 at 11:30 PM

2 · Reply

Bobcar888 Feb. 3 at 10:50 PM

2 · Reply

StonkZombie Feb. 3 at 10:49 PM

2 · Reply

Schindelegger Feb. 3 at 10:46 PM

3 · Reply

Biorocksme Feb. 3 at 10:40 PM

$ITRM The only step down with real world data is this stock price.

0 · Reply

Shawshank256 Feb. 3 at 10:22 PM

$ITRM yesterday 1.1 mil avail to borrow ,today 1.8mil ,both days 76-77% dark pool trading vol with accumulation up

0 · Reply

ibraa1313 Feb. 3 at 9:53 PM

1 · Reply

gandolf63 Feb. 3 at 9:42 PM

$ITRM it would be something if word leaked a deal with pfizer was ”being considered” before the vote? watch the sp shoot to a dollar

0 · Reply

Htk1 Feb. 3 at 9:34 PM

$ITRM might make them as stressed as we are right now.

0 · Reply

Htk1 Feb. 3 at 9:34 PM

$ITRM how many times can we change a vote? Should spice things up and start changing it every other day 😆

0 · Reply

Shawshank256 Feb. 3 at 9:16 PM

$ITRM one side Orlynvah getting insurance adoption ,other side management and no money for scaling up ,place ur bets

0 · Reply

DollerADay Feb. 3 at 9:15 PM

$ITRM I don’t want to tip my hand about the movement the past several days but it’s crystal clear a bullish signal. Especially today when you triangulate the Active Bids/asks/neutral relative to exchange weighting. A major signal is the NSD and Impact bio was hired the last week in Dec and at least 3 other sales managers in Jan. This is done for one of two reasons. All signs point to a triple crown, good news is Mon is the last day it can happen. If no negative news Fri AH (could they really have fucked this up and could they hold a Step Down that was negative this long?) Also, there is a reason third party agencies call certain shareholders. The reason million-share retail holders are not called or having their call returned simultaneously…; in a situation like this, it’s typically really good.😉

2 · Reply

gogo66so Feb. 3 at 9:08 PM

$ITRM For those asking, While Iterum's official business updates often omit specific PBM names, recent coverage data indicates that Aetna (owned by CVS Health, which also owns CVS Caremark) already includes Orlynvah in portions of its plans. Additionally, OptumRx published a drug approval resource for Orlynvah shortly after its FDA approval, signaling active integration into their systems. That leaves Cigna, Express Scripts, and they have already included in about 30 percent of better plans. You will need to enter Orlynvah in the search at top right and it will highlight Orlynvah where it is included or excluded. https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fstatic.cigna.com%2Fassets%2Fchcp%2Fpdf%2FcoveragePolicies%2Fcnf%2Fcompanion_doc_cnf001_cnf002.xlsx&wdOrigin=BROWSELINK

0 · Reply

gogo66so Feb. 3 at 8:43 PM

$ITRM I also got a call today from Mike Lindell (the pillow guy) asking for my vote.

2 · Reply

yellowjacker Feb. 3 at 8:25 PM

$ITRM Gemini has been put on high alert for any filing pertaining to Iterum in the US and Ireland data bases. Nothing is coming up at the present time. Another sign that something is brewing because a nondisclosure agreement has been sign, Which BO companies prefer while in negotiations. Add on no stepdown letter and a late earning report makes you wonder.

1 · Reply

gabyrig Feb. 3 at 8:23 PM

$ITRM 🤣😂 Thank you Stocktwits

1 · Reply

yellowjacker Feb. 3 at 8:19 PM

$ITRM Go figure. Gemini told me today that warrants were allowed to expire today. A bullish sign that Fishman does need any money for the time being and allow the warrant to expire. A BO positive.

1 · Reply

yellowjacker Feb. 3 at 8:10 PM

$ITRM Think of it this way. Fishman and the board are in the front seat driving the Iterum car. Stockholer are in the backseat trying to get to the pomise land. The vultures (Big pharma} are circling above us hoping Fishman wrecks the car so they can pick our bones.

1 · Reply

gandolf63 Feb. 3 at 8:02 PM

$ITRM PfizerUpcoming patent expirations are adding fuel to the fire and will soon lead to $17 billion in lost revenue, leading to negative earnings growth projections from analysts.” https://stocks.apple.com/AlpfqvltuTc-XF-7EQPwTVA

0 · Reply

Market Cap	16.36M
Revenue (ttm)	0.00
Net Income (ttm)	-24.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-2.88

Volume	417,800
Avg Vol	787,130
Day's Range	N/A - N/A
Shares Out	53.29M
Stochastic %K	11%
Beta	2.87
Analysts	Strong Sell
Price Target	$5.50